Becton Dickinson Total Long Term Liabilities 2010-2024 | BDX
Becton Dickinson total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Becton Dickinson total long term liabilities for the quarter ending June 30, 2024 were $23.109B, a 14.38% increase year-over-year.
- Becton Dickinson total long term liabilities for 2023 were $20.343B, a 2.54% increase from 2022.
- Becton Dickinson total long term liabilities for 2022 were $19.84B, a 15.8% decline from 2021.
- Becton Dickinson total long term liabilities for 2021 were $23.564B, a 3.47% decline from 2020.
Becton Dickinson Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$20,343 |
| 2022 |
$19,840 |
| 2021 |
$23,564 |
| 2020 |
$24,412 |
| 2019 |
$25,029 |
| 2018 |
$25,693 |
| 2017 |
$21,444 |
| 2016 |
$13,553 |
| 2015 |
$14,933 |
| 2014 |
$5,160 |
| 2013 |
$4,976 |
| 2012 |
$5,247 |
| 2011 |
$3,779 |
| 2010 |
$2,544 |
| 2009 |
$2,385 |
Becton Dickinson Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-06-30 |
$23,109 |
| 2024-03-31 |
$21,182 |
| 2023-12-31 |
$19,402 |
| 2023-09-30 |
$20,343 |
| 2023-06-30 |
$20,203 |
| 2023-03-31 |
$21,401 |
| 2022-12-31 |
$20,032 |
| 2022-09-30 |
$19,840 |
| 2022-06-30 |
$20,626 |
| 2022-03-31 |
$23,605 |
| 2021-12-31 |
$22,468 |
| 2021-09-30 |
$23,564 |
| 2021-06-30 |
$22,450 |
| 2021-03-31 |
$24,718 |
| 2020-12-31 |
$23,065 |
| 2020-09-30 |
$24,412 |
| 2020-06-30 |
$23,870 |
| 2020-03-31 |
$23,809 |
| 2019-12-31 |
$24,024 |
| 2019-09-30 |
$25,029 |
| 2019-06-30 |
$24,499 |
| 2019-03-31 |
$24,181 |
| 2018-12-31 |
$24,384 |
| 2018-09-30 |
$25,693 |
| 2018-06-30 |
$26,513 |
| 2018-03-31 |
$28,994 |
| 2017-12-31 |
$29,220 |
| 2017-09-30 |
$21,444 |
| 2017-06-30 |
$21,306 |
| 2017-03-31 |
$12,140 |
| 2016-12-31 |
$12,164 |
| 2016-09-30 |
$13,553 |
| 2016-06-30 |
$13,765 |
| 2016-03-31 |
$14,191 |
| 2015-12-31 |
$14,294 |
| 2015-09-30 |
$14,933 |
| 2015-06-30 |
$15,310 |
| 2015-03-31 |
$16,637 |
| 2014-12-31 |
$11,355 |
| 2014-09-30 |
$5,160 |
| 2014-06-30 |
$4,903 |
| 2014-03-31 |
$4,919 |
| 2013-12-31 |
$4,960 |
| 2013-09-30 |
$4,976 |
| 2013-06-30 |
$5,178 |
| 2013-03-31 |
$5,163 |
| 2012-12-31 |
$5,156 |
| 2012-09-30 |
$5,247 |
| 2012-06-30 |
$4,901 |
| 2012-03-31 |
$5,098 |
| 2011-12-31 |
$5,079 |
| 2011-09-30 |
$3,779 |
| 2011-06-30 |
$3,664 |
| 2011-03-31 |
$3,666 |
| 2010-12-31 |
$3,581 |
| 2010-09-30 |
$2,544 |
| 2010-06-30 |
$2,346 |
| 2010-03-31 |
$2,326 |
| 2009-12-31 |
$2,295 |
| 2009-09-30 |
$2,385 |
| 2009-06-30 |
$1,991 |
| 2009-03-31 |
$1,261 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$66.939B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
